NEWS
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
Nektar Therapeutics (NKTR) presented preclinical data for NKTR-422, a novel modified CSF protein, at the 2024 ACR conference. The drug demonstrated promising results in inflammation resolution and tissue repair across multiple preclinical models. NKTR-422functions by targeting anti-inflammatory tissue resident macrophages and shows a differentiated PK/PD profile compared to native CSF-1 cytokine, requiring only single doses rather than multiple daily administrations. The compound showed potential to enhance efficacy when combined with inflammatory cytokine blockade treatments in rodent models.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2538Followers
107Following
28KVisitors
Follow